ActRIIB Polypeptide Truncations for Metabolic Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective agents to regulate signaling within the TGF-beta superfamily, particularly for treating disorders associated with muscle and metabolic issues such as obesity, insulin resistance, and muscle wasting.
Innovation Solution
Development of novel ActRIIB polypeptides, including amino- and carboxy-terminal truncations and sequence alterations, which bind to ActRIIB ligands like GDF8 and BMP7, promoting lean body mass gain and fat mass reduction, thereby addressing metabolic and muscle-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used, then current treatment options are limited, but effective regulation of TGF-beta superfamily signaling is not achieved
Solution Approach 1:
The patent applies parameter changes by modifying the ActRIIB polypeptide structure through amino- and carboxy-terminal truncations and sequence alterations. These structural parameter changes create novel polypeptides with optimized binding properties to ActRIIB ligands, enabling effective regulation of TGF-beta superfamily signaling while maintaining therapeutic reliability for treating metabolic and muscle disorders
2Reliability
If full-length ActRIIB polypeptides are used, then ligand binding is achieved, but complexity of the molecule increases
Solution Approach 1:
The patent applies segmentation by dividing the full-length ActRIIB polypeptide into truncated segments. Specifically, amino- and carboxy-terminal truncations create smaller polypeptide fragments (e.g., residues 25-131) that retain ligand binding capability while reducing overall molecular complexity. This segmentation maintains therapeutic efficacy with simplified molecular structures
Solution Approach 2:
The patent applies the extraction principle by removing specific terminal regions (amino- and carboxy-terminal portions) from the full-length ActRIIB polypeptide. These extracted segments are non-essential for core ligand binding function, allowing creation of truncated polypeptides with reduced complexity that preserve the essential binding and signaling regulatory functions
Data Source
AI summary
In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, brown fat and/or neuronal tissue and for treating metabolic disorders such as diabetes and obesity, as well as disorders associated with any of the foregoing tissue.